Cerveau technologies inc. and alnylam® pharmaceuticals sign agreement to provide novel tau imaging biomarker for disease modifier research

Boston--(business wire)--cerveau technologies, inc. today announced a research collaboration agreement with alnylam® pharmaceuticals (alnylam), which will enable alnylam to use cerveau's [f-18]mk-6240, an investigational imaging agent, in positron emission tomography (pet) scans to assess the status and progression of neurofibrillary tangles (nfts) in the brain. nfts made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including alzheimer's disease. the collab
ALNY Ratings Summary
ALNY Quant Ranking